Ruxolitinib plus venetoclax and azacitidine for relapsed AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase study tests a combination of ruxolitinib with venetoclax, with or without azacitidine, for adults whose acute myeloid leukemia (AML) has come back or does not respond to treatment. It may help by stopping cancer cells from growing and improving blood counts, with the exact plan guided by the study arm you’re assigned to.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and able to sign informed consent
- Your AML is relapsed or refractory after at least one prior AML treatment
- Your leukemia is not the APL subtype (AML M3)
- Your general health is fair (ECOG score 0 to 2)
- You can take and absorb by mouth study medicines, and your kidney/liver blood tests are within limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
This trial tests a combination of three drugs (tagraxofusp, azacitidine, and venetoclax) for people newly diagnosed with a type of acute myeloid leukemia (AML) that has developed after treatment with certain prior drugs (hypomethylating agents). The goal is to see if this combination is safe and effective.
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
Hear when a new Recurrent Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.